A day after FDA approved Sarepta Therapeutics Inc.'s Exondys 51 (eteplirsen), the company won a favorable ruling from the patent office enabling it to obtain a composition of matter patent on the Duchenne muscular dystrophy drug.
The US Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) issued a Sept. 20 order against...




